Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Survival Data Keeps Roche Ahead In TIGIT Immunotherapy Race

But Can It Really Challenge Keytruda Dominance?

Executive Summary

Roche’s Phase II lung cancer results bode well for SKYSCRAPER readout expected in 2022.

You may also be interested in...



Roche’s Phase III TIGIT Failure In Metastatic SCLC Disappoints But Is Small Loss

Tiragolumab missed several endpoints in a Phase III metastatic SCLC study, and hopes now rest on its success in NSCLC which presents the bigger market opportunity for the lead candidate in this closely watched new drug class.

Readouts For TIGIT And Alzheimer’s Drugs Will Define Roche’s Year

Roche has a lot riding on it trials to extend use of Tecentriq to challenge Keytruda in frontline NSCLC – but the wait for its Alzheimer’s readout for gantenerumab will be truly nerve-wracking.

Sanofi Alliance Is Big Boost For Company Behind Type 1 Diabetes Prevention Drug

Sanofi has deprioritized its presence in type 1 diabetes in recent years but could help turn teplizumab into a game-changer blockbuster product.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145560

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel